Literature DB >> 845484

Breakdown products of C3 and factor B in hemolytic-uremic syndrome.

Y Kim, K Miller, A F Michael.   

Abstract

Serum concentrations of Clq, C4, C3, and Factor B but not properdin were significantly decreased in patients with HUS compared to values in normal control subjects (p value less than 0.01). Sera from 13 HUS patients obtained early after the onset of the disease showed breakdown products of Factor B (Ba, Bb) by immunoelectrophoresis; 12 of these sera showed C3 breakdown products (C3c, C3d). Sera from seven patients studied 1 month to 3 years later no longer demonstrated any breakdown products of Factor B or C3. These data suggest that the complemented system is activate in HUS. The concept that immunological mechanisms play a major role in this disease is additionally supported by the occurrence of IgM, C3, and fibrin in glomeruli and renal vessels.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 845484

Source DB:  PubMed          Journal:  J Lab Clin Med        ISSN: 0022-2143


  14 in total

1.  Recurrent haemolytic-uraemic syndrome with hypocomplementaemia: a case report.

Authors:  R Bogdanović; A Cvorić; V Nikolić; M Sindjić
Journal:  Pediatr Nephrol       Date:  1988-04       Impact factor: 3.714

2.  Possible C1q bypass loop activation in the haemolytic uraemic syndrome.

Authors:  L Nolin; S O'Regan; M Pelletier; G E Rivard; J G Mongeau; P Robitaille
Journal:  Clin Exp Immunol       Date:  1979-01       Impact factor: 4.330

Review 3.  [Clinical aspects of the hemolytic-uremic syndrome].

Authors:  M Brandis
Journal:  Klin Wochenschr       Date:  1979-10-01

4.  Acute glomerulonephritis and hemolytic uremic syndrome.

Authors:  J P de Chadarévian; P R Goodyer; B S Kaplan
Journal:  Can Med Assoc J       Date:  1980-09-06       Impact factor: 8.262

5.  Outbreak of Shiga toxin-producing Escherichia-coli-associated hemolytic uremic syndrome in Istanbul in 2015: outcome and experience with eculizumab.

Authors:  Ayşe Ağbaş; Nilüfer Göknar; Nurver Akıncı; Zeynep Yürük Yıldırım; Mehmet Taşdemir; Meryem Benzer; İbrahim Gökçe; Cengiz Candan; Nuran Küçük; Selçuk Uzuner; Gül Özçelik; Demet Demirkol; Lale Sever; Salim Çalışkan
Journal:  Pediatr Nephrol       Date:  2018-08-29       Impact factor: 3.714

6.  Alterations in serum opsonic activity and complement levels in pneumococcal disease.

Authors:  G S Giebink; T H Dee; Y Kim; P G Quie
Journal:  Infect Immun       Date:  1980-09       Impact factor: 3.441

7.  Mannan-binding lectin in children with Escherichia coli O157:H7 haemmorrhagic colitis and haemolytic uraemic syndrome.

Authors:  F Proulx; E Wagner; B Toledano; H Decaluwe; E G Seidman; G-E Rivard
Journal:  Clin Exp Immunol       Date:  2003-09       Impact factor: 4.330

8.  Effect of differences in antibody and complement requirements on phagocytic uptake and intracellular killing of "c" protein-positive and -negative strains of type II group B streptococci.

Authors:  N R Payne; Y K Kim; P Ferrieri
Journal:  Infect Immun       Date:  1987-05       Impact factor: 3.441

Review 9.  Pathogenesis of thrombotic microangiopathies.

Authors:  X Long Zheng; J Evan Sadler
Journal:  Annu Rev Pathol       Date:  2008       Impact factor: 23.472

Review 10.  Current evidence for the role of complement in the pathogenesis of Shiga toxin haemolytic uraemic syndrome.

Authors:  Lindsay S Keir; Moin A Saleem
Journal:  Pediatr Nephrol       Date:  2013-07-11       Impact factor: 3.714

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.